vs

Side-by-side financial comparison of Palladyne AI Corp. (PDYN) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

TScan Therapeutics, Inc. is the larger business by last-quarter revenue ($2.6M vs $1.7M, roughly 1.5× Palladyne AI Corp.). Palladyne AI Corp. runs the higher net margin — -89.9% vs -895.1%, a 805.2% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs 118.3%). Palladyne AI Corp. produced more free cash flow last quarter ($-8.7M vs $-32.2M). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -30.5%).

Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

PDYN vs TCRX — Head-to-Head

Bigger by revenue
TCRX
TCRX
1.5× larger
TCRX
$2.6M
$1.7M
PDYN
Growing faster (revenue YoY)
TCRX
TCRX
+167.7% gap
TCRX
286.0%
118.3%
PDYN
Higher net margin
PDYN
PDYN
805.2% more per $
PDYN
-89.9%
-895.1%
TCRX
More free cash flow
PDYN
PDYN
$23.4M more FCF
PDYN
$-8.7M
$-32.2M
TCRX
Faster 2-yr revenue CAGR
TCRX
TCRX
Annualised
TCRX
-9.7%
-30.5%
PDYN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PDYN
PDYN
TCRX
TCRX
Revenue
$1.7M
$2.6M
Net Profit
$-1.5M
$-23.0M
Gross Margin
15.6%
Operating Margin
-560.7%
-929.4%
Net Margin
-89.9%
-895.1%
Revenue YoY
118.3%
286.0%
Net Profit YoY
97.2%
35.8%
EPS (diluted)
$-0.02
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PDYN
PDYN
TCRX
TCRX
Q4 25
$1.7M
$2.6M
Q3 25
$860.0K
$2.5M
Q2 25
$1.0M
$3.1M
Q1 25
$1.7M
$2.2M
Q4 24
$761.0K
Q3 24
$871.0K
$1.0M
Q2 24
$2.7M
Q1 24
$3.4M
Net Profit
PDYN
PDYN
TCRX
TCRX
Q4 25
$-1.5M
$-23.0M
Q3 25
$-3.7M
$-35.7M
Q2 25
$-7.5M
$-37.0M
Q1 25
$22.8M
$-34.1M
Q4 24
Q3 24
$-7.1M
$-29.9M
Q2 24
$-5.3M
Q1 24
$-7.2M
Gross Margin
PDYN
PDYN
TCRX
TCRX
Q4 25
15.6%
Q3 25
46.4%
Q2 25
53.3%
Q1 25
79.4%
Q4 24
27.2%
Q3 24
45.0%
Q2 24
79.0%
Q1 24
45.2%
Operating Margin
PDYN
PDYN
TCRX
TCRX
Q4 25
-560.7%
-929.4%
Q3 25
-937.8%
-1475.6%
Q2 25
-797.4%
-1256.6%
Q1 25
-405.3%
-1669.7%
Q4 24
Q3 24
-838.0%
-3109.8%
Q2 24
-213.3%
Q1 24
-213.7%
Net Margin
PDYN
PDYN
TCRX
TCRX
Q4 25
-89.9%
-895.1%
Q3 25
-434.9%
-1422.1%
Q2 25
-737.6%
-1201.3%
Q1 25
1330.9%
-1571.9%
Q4 24
Q3 24
-814.7%
-2849.1%
Q2 24
-196.2%
Q1 24
-210.1%
EPS (diluted)
PDYN
PDYN
TCRX
TCRX
Q4 25
$-0.02
$-0.18
Q3 25
$-0.09
$-0.28
Q2 25
$-0.20
$-0.28
Q1 25
$0.55
$-0.26
Q4 24
Q3 24
$-0.27
$-0.25
Q2 24
$-0.20
Q1 24
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PDYN
PDYN
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$47.1M
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$74.7M
$123.1M
Total Assets
$95.7M
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PDYN
PDYN
TCRX
TCRX
Q4 25
$47.1M
$152.4M
Q3 25
$57.1M
$184.5M
Q2 25
$62.7M
$218.0M
Q1 25
$46.6M
$251.7M
Q4 24
$40.1M
Q3 24
$21.3M
$271.1M
Q2 24
$25.8M
Q1 24
$31.8M
Total Debt
PDYN
PDYN
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
PDYN
PDYN
TCRX
TCRX
Q4 25
$74.7M
$123.1M
Q3 25
$51.8M
$144.0M
Q2 25
$53.8M
$176.7M
Q1 25
$28.3M
$210.2M
Q4 24
$-9.5M
Q3 24
$23.4M
$229.1M
Q2 24
$29.8M
Q1 24
$34.2M
Total Assets
PDYN
PDYN
TCRX
TCRX
Q4 25
$95.7M
$228.8M
Q3 25
$72.9M
$262.2M
Q2 25
$78.3M
$298.6M
Q1 25
$63.3M
$332.7M
Q4 24
$56.3M
Q3 24
$38.7M
$348.0M
Q2 24
$45.1M
Q1 24
$50.4M
Debt / Equity
PDYN
PDYN
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PDYN
PDYN
TCRX
TCRX
Operating Cash FlowLast quarter
$-8.5M
$-32.0M
Free Cash FlowOCF − Capex
$-8.7M
$-32.2M
FCF MarginFCF / Revenue
-526.2%
-1253.3%
Capex IntensityCapex / Revenue
14.2%
6.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PDYN
PDYN
TCRX
TCRX
Q4 25
$-8.5M
$-32.0M
Q3 25
$-6.3M
$-32.5M
Q2 25
$-5.3M
$-33.3M
Q1 25
$-7.5M
$-37.6M
Q4 24
$-22.6M
Q3 24
$-4.5M
$-27.9M
Q2 24
$-5.8M
Q1 24
$-7.2M
Free Cash Flow
PDYN
PDYN
TCRX
TCRX
Q4 25
$-8.7M
$-32.2M
Q3 25
$-6.7M
$-33.9M
Q2 25
$-34.5M
Q1 25
$-7.6M
$-39.1M
Q4 24
$-22.9M
Q3 24
$-4.5M
$-29.3M
Q2 24
$-5.9M
Q1 24
$-7.3M
FCF Margin
PDYN
PDYN
TCRX
TCRX
Q4 25
-526.2%
-1253.3%
Q3 25
-776.0%
-1349.6%
Q2 25
-1123.1%
Q1 25
-445.0%
-1801.8%
Q4 24
-3008.1%
Q3 24
-517.8%
-2792.0%
Q2 24
-218.9%
Q1 24
-212.1%
Capex Intensity
PDYN
PDYN
TCRX
TCRX
Q4 25
14.2%
6.7%
Q3 25
44.7%
56.8%
Q2 25
0.0%
41.6%
Q1 25
5.4%
70.6%
Q4 24
34.8%
Q3 24
1.4%
130.6%
Q2 24
5.3%
Q1 24
1.8%
Cash Conversion
PDYN
PDYN
TCRX
TCRX
Q4 25
Q3 25
Q2 25
Q1 25
-0.33×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons